Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. The company operates in two segments: Technology and Professional Services. It offers ignite data and analytics platform that provides clients a single comprehensive environment to integrate and organize data from their disparate software systems; and applications, a software analytics applications build for ignite platform to analyze clients face across clinical improvement, revenue and cost improvement, ambulatory operations, measures and registries, and data and analytics. The company also provides expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. It serves academic medical centers, integrated delivery networks, community hospitals, large physician practices, accountable care organizations, health information exchanges, health insurers, life science organizations, healthcare technology vendors, and other risk-bearing entities. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.…
HCAT Q3 2026 deep dive: client retention and cost alignment take center stage
Health Catalyst (NASDAQ: HCAT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 1,200 employees.
The shares were at 1.310 USD on 20 November 2026, down 53.7% over 52 weeks. Its 52-week range is 0.9550 USD to 3.360 USD: the price is 61.0% below the high and 37.2% above the low.
Its market capitalisation is 99.76M USD.
Health Catalyst reports return on equity of -72.4%, an operating margin of -9.9% and revenue down 26.3% year over year.
It holds more cash than debt, a net cash position of 63.24M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Hold; their mean price target of 1.767 USD is 34.9% above the current price. The next earnings report is expected on 11 March 2027.